Co-Founder & CEO

Dr. Hasam Madarati has graduated from McMaster University's Medical Science Ph.D. program with a specialization in Blood & Vasculature. Hasam has 7 years of experience in the biotechnology field, and more than 5 years of experience specializing in the hematology field. To date, Hasam has been part of 5 journal article publications and a book chapter on the role of ADAMTS13 in sepsis. He has several collaborations in the science field and has honed his business acumen through participation in mini-MBA program (GMCA), health innovation bootcamp and residency program (the Clinic), and has led Rayyan Therapeutics in the Synapse Life Science Consortium competition. 

Co-Founder & CSO

Dr. Colin Kretz has graduated from McMaster University's Medical Science Ph.D. program with a specialization in Blood & Vasculature. Colin is an Associate Professor at McMaster University with a wealth of experience in hematology research and has established a successful research lab at TaARI - McMaster. With 18 years of experience in the hematology research Colin is an invaluable asset to the team. He has also obtained over $1M in funding for his research programs from sources such as the Canadian Institutes of Health Research (CIHR), demonstrating his ability to secure funding and support for his research initiatives. His experience is very valuable in further developing the product and technology at Rayyan Therapeutics. 

Scientific Adviser

Dr. Patricia Liaw is a scientific advisor for Rayyan Therapeutics, who evaluates novel pre-clinical strategies for the treatment of sepsis. For over 10 years, she has established a research lab at TaARI and is part of a clinical trial that looks at the use of DNase 1 and heparin in septic patients. She is funded by CIHR and is a professor at McMaster University. She also chairs the Canadian Critical Care Translation Biology Group (CCCTBG). 

Scientific Adviser

Dr. Alison Fox-Robichaud, MD, is another clinician scientific advisor for Rayyan Therapeutics and an Associate Professor at McMaster University. She focuses on basic and clinical science research in sepsis and is the current Chair at the RCPSC Critical Care Examination Board and is the scientific leader of Sepsis Canada. She led an observational study for various biomarkers of sepsis and is also part of the Canadian Critical Care Translational Biology Group (CCCTBG).

BDC Student - McMaster University

Ibrahim Ilahi is a student at McMaster University who is graduating this year from the Biomedical Discovery & Commercialization program. He has experience in developing commercialization plans for medical devices and pharmaceuticals, which is a valuable asset to Rayyan Therapeutics as we move forward with our plans.